Alzheimers Drug Acting on Hippocampus in Alzheimers Disease Comment by Intern at Roskamp Institute
Home > BlogEffects of an experimental drug, (Val8)GLP-1

Effects of an experimental drug, (Val8)GLP-1

Posted by MullanMichael on September 21, 2012

Researchers at the Biomedical Science Institute (BMSRI) recently had their study published in the September 14 edition of Brain Research. This study focused on the effects of an experimental drug, (Val8)GLP-1, on cell growth in the hippocampus, an area of the brain that plays an important role in memory. This experimental drug is designed to treat diabetes II, a disease that does increase the risk of Alzheimer’s disease. Therefore, the researchers at BMSRI believed the drug would be effective for the treatment of Alzheimer’ disease.

            (Val8)GLP-1 controls blood sugar levels in the body by stimulating GLP-1. When the scientists tested (Val8)GLP-1 on healthy mice, they found that the drug could easily cross the blood-brain barrier with little side-effects. The presence of GLP-1 incited the production of nerve cells in the hippocampus, but caused the mice to perform poorly on memory tests when its effects were inhibited.

            Further studies have to be conducted to test the validity of these results, but these findings indicate that GLP-1 could be a potential target for treating Alzheimer’s disease. (Moore)

 

 

Source:

Moore, Amber. "Experimental Diabetes Drug Could Combat Alzheimer's." Medical Daily. MedicalDaily.com, 17 Sep 2012. Web. 19 Sep 2012. <http://www.medicaldaily.com/articles/12145/20120917/experimental-diabetes-drug-combat-alzheimers.htm>.

 

Wendy Liu

Sept. 19, 2012